<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Clin Transl Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin Transl Med</journal-id>
<journal-title-group>
<journal-title>Clinical and Translational Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2001-1326</issn>
<publisher>
<publisher-name>Springer Berlin Heidelberg</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28405929</article-id>
<article-id pub-id-type="pmc">5389954</article-id>
<article-id pub-id-type="publisher-id">144</article-id>
<article-id pub-id-type="doi">10.1186/s40169-017-0144-7</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT/beta-catenin pathway</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0437-4862</contrib-id>
<name>
<surname>Lecarpentier</surname>
<given-names>Yves</given-names>
</name>
<address>
<email>yves.c.lecarpentier@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Claes</surname>
<given-names>Victor</given-names>
</name>
<address>
<email>victor.claes@scarlet.be</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vallée</surname>
<given-names>Alexandre</given-names>
</name>
<address>
<email>vallee_alex@yahoo.fr</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hébert</surname>
<given-names>Jean-Louis</given-names>
</name>
<address>
<email>jean.l.hebert@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<aff id="Aff1"><label>1</label>Centre de Recherche Clinique, Hôpital de Meaux, 6-8 rue Saint Fiacre, 77100 Meaux, France </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.5284.b</institution-id><institution>Department of Pharmaceutical Sciences, </institution><institution>University of Antwerp, </institution></institution-wrap>Wilrijk, Belgium </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.11166.31</institution-id><institution>Experimental and Clinical Neurosciences Laboratory, INSERM U1084, </institution><institution>University of Poitiers, </institution></institution-wrap>Poitiers, France </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution>Institut de Cardiologie, </institution><institution>Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, </institution></institution-wrap>Paris, France </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>12</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>12</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>6</volume>
<elocation-id>14</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>11</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>3</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>Cancer cells are the site of numerous metabolic and thermodynamic abnormalities. We focus this review on the interactions between the canonical WNT/beta-catenin pathway and peroxisome proliferator-activated receptor gamma (PPAR gamma) in cancers and their implications from an energetic and metabolic point of view. In numerous tissues, PPAR gamma activation induces inhibition of beta-catenin pathway, while the activation of the canonical WNT/beta-catenin pathway inactivates PPAR gamma. In most cancers but not all, PPAR gamma is downregulated while the WNT/beta-catenin pathway is upregulated. In cancer cells, upregulation of the WNT/beta-catenin signaling induces dramatic changes in key metabolic enzymes that modify their thermodynamic behavior. This leads to activation of pyruvate dehydrogenase kinase1 (PDK-1) and monocarboxylate lactate transporter. Consequently, phosphorylation of PDK-1 inhibits the pyruvate dehydrogenase complex (PDH). Thus, a large part of pyruvate cannot be converted into acetyl-coenzyme A (acetyl-CoA) in mitochondria and only a part of acetyl-CoA can enter the tricarboxylic acid cycle. This leads to aerobic glycolysis in spite of the availability of oxygen. This phenomenon is referred to as the Warburg effect. Cytoplasmic pyruvate is converted into lactate. The WNT/beta-catenin pathway induces the transcription of genes involved in cell proliferation, i.e., MYC and CYCLIN D1. This ultimately promotes the nucleotide, protein and lipid synthesis necessary for cell growth and multiplication. In cancer, activation of the PI3K-AKT pathway induces an increase of the aerobic glycolysis. Moreover, prostaglandin E2 by activating the canonical WNT pathway plays also a role in cancer. In addition in many cancer cells, PPAR gamma is downregulated. Moreover, PPAR gamma contributes to regulate some key circadian genes. In cancers, abnormalities in the regulation of circadian rhythms (CRs) are observed. CRs are dissipative structures which play a key-role in far-from-equilibrium thermodynamics. In cancers, metabolism, thermodynamics and CRs are intimately interrelated.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>PPAR gamma</kwd>
<kwd>WNT/beta-catenin</kwd>
<kwd>Cancer</kwd>
<kwd>Circadian rhythms</kwd>
<kwd>Pyruvate dehydrogenase kinase</kwd>
<kwd>Pyruvate dehydrogenase complex</kwd>
<kwd>Aerobic glycolysis</kwd>
<kwd>Warburg effect</kwd>
<kwd>PI3 K-AKT pathway</kwd>
<kwd>Dissipative structures</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p>Schrödinger in his famous book “What is life” [<xref ref-type="bibr" rid="CR1">1</xref>] provided us a new understanding of the thermodynamics in living systems. By applying this to the thermodynamics of physical, chemical and biological far-from-equilibrium systems, Prigogine and his colleagues opened new avenues for the exploration of dissipative structures which occupy a major place in the living world [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Cancer is an exergonic process in which heat flows from the tumor to its surroundings [<xref ref-type="bibr" rid="CR4">4</xref>]. The entropy production rate is increased in cancer cells and is characteristic of irreversible processes driven by changes in heat production, Gibbs energy, intracellular acidity, ionic conductance, membrane potential gradient [<xref ref-type="bibr" rid="CR5">5</xref>]. Numerous cellular mechanisms can induce and develop carcinogenic processes. In most cancers, the WNT/beta-catenin pathway is upregulated while peroxisome proliferator-activated receptor gamma (PPAR gamma) is downregulated. This profile has been observed in several diseases [<xref ref-type="bibr" rid="CR6">6</xref>] such as cancers [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], type 2 diabetes [<xref ref-type="bibr" rid="CR9">9</xref>], and certain neurodegenerative diseases (amyotrophic lateral sclerosis [<xref ref-type="bibr" rid="CR10">10</xref>], Huntington’s disease [<xref ref-type="bibr" rid="CR11">11</xref>], multiple sclerosis [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>] and Friedreich’s ataxia [<xref ref-type="bibr" rid="CR14">14</xref>]). The opposite profile has been reported in arrhythmogenic right ventricular cardiomyopathy (ARVC) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], osteoporosis [<xref ref-type="bibr" rid="CR17">17</xref>–<xref ref-type="bibr" rid="CR19">19</xref>], and certain neurodegenerative diseases (Alzheimer’s disease [<xref ref-type="bibr" rid="CR20">20</xref>], Parkinson’s disease [<xref ref-type="bibr" rid="CR21">21</xref>], bipolar disorder [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>] and schizophrenia [<xref ref-type="bibr" rid="CR24">24</xref>]). From a thermodynamic viewpoint and among numerous cellular processes involved in cancers, two major phenomena play a key role, i.e., aerobic glycolysis or the Warburg effect and disruption of circadian rhythms (CRs). The thermodynamic dysregulation induced by these two processes is consubstantial with metabolic abnormalities commonly found in cancers. PPAR dysfunction influences statistical mechanics by modifying thermodynamic force, thermodynamic flow, and rate of entropy production [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. We focus our review on the opposing interactions observed in cancers between the canonical WNT/beta-catenin pathway and PPAR gamma and their metabolic and energetic implications.</p>
<sec id="Sec2">
<title>Canonical WNT/beta-catenin pathway</title>
<p>The canonical WNT/beta-catenin pathway plays an important role in metabolism, embryonic development, cell fate, and epithelial-mesenchymal transition (EMT) <underline>[</underline>
<xref ref-type="bibr" rid="CR26">26</xref>
<underline>]</underline>. The canonical WNT activity is reflected by elevated levels of beta-catenin in the nucleus and/or cytoplasm, which can be detected by means of immunohistochemical staining, Western blotting and semiquantitative RT-PCR [<xref ref-type="bibr" rid="CR27">27</xref>]. Its dysfunction is involved in numerous diseases, particularly in cancers [<xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR31">31</xref>]. The transcription factor beta-catenin/T-cell factor/lymphoid enhancer factor (TCF/LEF) represents the key effector of the canonical WNT pathway (Figs. <xref ref-type="fig" rid="Fig1">1</xref>, <xref ref-type="fig" rid="Fig2">2</xref>). The destruction complex consists of AXIN, tumor suppressor adenomatous polyposis coli (APC), and glycogen synthase kinase-3 (GSK-3beta). The destruction complex exerts a tight control on the beta-catenin signaling. In the absence of WNT ligands (“off state”), the destruction complex phosphorylates beta-catenin which is then degraded in the proteasome. In the presence of WNT ligands (“on state”), the WNT receptor interacts with Frizzled (FZL) and LDL receptor-related protein 5/6 (LRP5/6). WNT receptor is associated with Dishevelled (DSH). This triggers the disruption of the destruction complex and prevents degradation of beta-catenin in the proteasome. Beta-catenin then translocates to the nucleus and interacts with TCF/LEF. This leads to the stimulation of the beta-catenin target genes (pyruvate dehydrogenase kinase (PDK), monocarboxylate lactate transporter-1 (MTC-1), MYC, CYCLIN D1, cyclooxygenase-2 (COX-2), AXIN) [<xref ref-type="bibr" rid="CR32">32</xref>–<xref ref-type="bibr" rid="CR35">35</xref>] (Fig. <xref ref-type="fig" rid="Fig1">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Schema of interactions between the canonical WNT/beta-catenin pathway and PPAR gamma under aerobic glycolysis conditions in cancer. In the absence of the WNT ligands (“off state”), cytosolic beta-catenin is phosphorylated by GSK-3 beta. APS and AXIN combine with GSK-3 beta and beta-catenin to enhance the destruction process in the proteasome. In the presence of the WNT ligands (“on state”), Wnt binds both Frizzled and LRP5/6 receptors to initiate LRP phosphorylation and dishevelled-mediated Frizzled internalization. This leads to dissociation of the AXIN/APC/GSK-3 beta complex. Beta-catenin phosphorylation is inhibited which prevents its degradation in the proteasome. Thus, beta-catenin accumulates in the cytosol and then translocates to the nucleus to bind TCF-LEF co-transcription factors. This induces the WNT-response gene transcription (PDK, MCT-1, MYC, CYCLIN D1). Glucose itself activates the WNT pathway. PPAR gamma inhibits the beta-catenin/TCF-LEF-induced activation of WNT target genes. PDK inhibits the PDH complex in mitochondria. Thus pyruvate cannot be fully converted into acetyl-CoA and enter the TCA cycle. MYC activates LDH-A which converts cytosolic pyruvate into lactate. MCT-1 favors lactate extrusion out of the cytosol which favors angiogenesis. MYC increases glutamine entry in the cytosol and mitochondria. MYC-induced glutamine enhances aspartate and nucleotide synthesis. <italic>APC</italic> adenomatous polyposis coli, <italic>alpha</italic>-<italic>KG</italic> alpha ceto-glutarate, <italic>DSH</italic> Dishevelled, <italic>FZD</italic> Frizzled, <italic>GSK</italic>-<italic>3beta</italic> glycogen synthase kinase-3beta, <italic>LDH</italic> lactate dehydrogenase, <italic>LRP5/6</italic> low-density lipoprotein receptor-related protein 5/6, <italic>MCT</italic>-<italic>1</italic> monocarboxylate lactate transporter-1, OAA: oxalo-acetic acid, <italic>PPAR gamm</italic> peroxisome proliferator-activated receptor gamma, <italic>PDH</italic> pyruvate dehydrogenase complex, <italic>PDK</italic> pyruvate dehydrogenase kinase, <italic>RTK</italic> receptor tyrosine kinase, <italic>TCF/LEF</italic> T-cell factor/lymphoid enhancer factor, <italic>TCA</italic> tricarboxylic acid, *WNT targets: PDK, MCT-1, MYC, CYCLIN D1</p></caption><graphic id="MO1" xlink:href="40169_2017_144_Fig1_HTML"></graphic></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Synthetic diagram of opposing effects of PPAR gamma and canonical WNT/beta-catenin signaling in cancer. <italic>Green arrow</italic> activation; <italic>red arrow</italic> inhibition; <italic>A</italic>-<italic>CoA</italic> acetyl-CoA, <italic>GSK</italic>-<italic>3beta</italic> glycogen synthase kinase-3beta, <italic>IC lactate</italic> intracellular lactate, <italic>EC lactate</italic> extracellular lactate, <italic>GSK</italic>-<italic>3beta</italic> glycogen synthase kinase-3beta, <italic>LDH</italic>-<italic>A</italic> lactico-dehydrogenase-A, <italic>MCT</italic>-<italic>1</italic> monocarboxylate lactate transporter-1, <italic>PI3</italic> <italic>K</italic>-<italic>AKT</italic> phosphatidylinositol 3-kinase-protein kinase B, <italic>PDH</italic> pyruvate dehydrogenase, <italic>PDK</italic> pyruvate dehydrogenase kinase, <italic>TCF/LEF</italic> T-cell factor/lymphoid enhancer factor, <italic>PPAR gamma</italic> peroxisome proliferator-activated receptor gamma</p></caption><graphic id="MO2" xlink:href="40169_2017_144_Fig2_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec3">
<title>PPAR gamma</title>
<p>Peroxisome proliferator-activated receptor gamma is a ligand-activated transcriptional factor that belongs to the nuclear hormone receptor superfamily [<xref ref-type="bibr" rid="CR36">36</xref>]. It heterodimerizes with the retinoid X receptor. PPAR gamma is expressed in numerous cell types, such as adipose tissues, muscles, brain, and immune cells. PPAR gamma activates the expression of many genes and regulates glucose homeostasis, insulin sensitivity, lipid metabolism, immune responses, cell fate and inflammation [<xref ref-type="bibr" rid="CR37">37</xref>–<xref ref-type="bibr" rid="CR39">39</xref>]. PPAR gamma agonists thiazolidinediones (TZDs) improve insulin sensitivity in peripheral tissues [<xref ref-type="bibr" rid="CR40">40</xref>] and ameliorate glucose tolerance and insulin sensitivity in type 2 diabetic patients [<xref ref-type="bibr" rid="CR41">41</xref>]. TZDs act on the promoters of glucose transporter (GLUT-2) and glucokinase (GK) in pancreatic beta-cells and liver. Abnormalities of PPAR gamma are observed in several pathological states such as cancers, diabetes, obesity, and atherosclerosis. Some TZDs have been used for treating type 2 diabetes. PPAR gamma also plays an important role in regulating cardiovascular rhythms by controlling circadian variations of blood pressure and heart rate through BMAL1 [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. However, numerous side effects induced by TZD have been reported [<xref ref-type="bibr" rid="CR44">44</xref>].</p>
</sec>
<sec id="Sec4">
<title>Opposing effects of the canonical WNT/beta-catenin pathway and PPAR gamma</title>
<p>The link between the WNT/beta-catenin pathway and PPAR gamma involves the TCF/LEF beta-catenin-binding domain and a catenin binding domain within PPAR gamma. In numerous mammalian cells, PPAR gamma and WNT/beta-catenin signaling behave in an opposite manner [<xref ref-type="bibr" rid="CR45">45</xref>–<xref ref-type="bibr" rid="CR50">50</xref>]. In some diseases, although the WNT/beta-catenin pathway is downregulated, PPAR gamma appears to be upregulated and vice versa (see: “<xref ref-type="sec" rid="Sec1">Introduction</xref>”) [<xref ref-type="bibr" rid="CR6">6</xref>]. In several cellular systems, beta-catenin is inhibited by PPAR gamma agonists [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. It has also been observed that inhibition of the WNT/beta-catenin pathway induces activation of PPAR gamma [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
</sec>
<sec id="Sec5">
<title>Aerobic glycolysis in cancer cells: role of the canonical WNT signaling</title>
<p>The role of the WNT/beta-catenin signaling in cancer development, especially in colorectal cancer, is now better understood [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Upregulation of the WNT/beta-catenin pathway via TCF/LEF leads to cell proliferation, EMT, migration and angiogenesis [<xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR56">56</xref>]. In cancer cells, overactivation of the WNT/beta-catenin pathway induces aerobic glycolysis. This allows glucose utilization for cell proliferation [<xref ref-type="bibr" rid="CR35">35</xref>]. Thus in a large part, glucose supply is fermented in lactate regardless of oxygen availability. This phenomenon is referred to as aerobic glycolysis or the Warburg effect [<xref ref-type="bibr" rid="CR57">57</xref>].</p>
<p>In cancer, the behavior of two key enzymes involved in glucose metabolism is modified leading to the Warburg effect. Activation of PDK-1 is required for the Warburg aerobic glycolysis. Upregulation of WNT/beta-catenin signaling activates both PDK-1 and MCT-1 [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. PDK-1, a major regulator of glucose metabolism, phosphorylates the pyruvate dehydrogenase complex (PDH) which is inhibited and largely prevents the conversion of pyruvate into acetyl-CoA in mitochondria [<xref ref-type="bibr" rid="CR59">59</xref>]. In colon cancer, PDK-1 is upregulated [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], so that the conversion of pyruvate into acetyl-CoA in mitochondria is diminished with a consequent reduction of acetyl-CoA entering the tricarboxylic acid (TCA) cycle. This induces aerobic glycolysis in spite of the availability of oxygen. PDK-1 has also been observed to be upregulated in several other cancers [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Cytosolic pyruvate is converted into lactate through activation of lactic dehydrogenase-A (LDH-A). Upregulation of both LDH-A and MCT-1 results in pyruvate being diverted towards the formation of lactate and the secretion of the latter outside of the cell, which favors angiogenesis [<xref ref-type="bibr" rid="CR63">63</xref>] and ultimately leads to anabolic production of biomass i.e., nucleotide synthesis [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. The Warburg effect partly shunts the TCA cycle leading to aerobic glycolysis which is less efficient in terms of ATP production. The most cost effective way producing ATP is via glucose oxidation (ATP/O<sub>2</sub> = 6.4), since the pathway via free fatty acid beta-oxidation is less efficient (ATP/O<sub>2</sub> = 5.6). This takes about 11% more O<sub>2</sub> to produce the same amount of ATP from fatty acids as it does from glucose. Moreover, PDK-1 and 2 enhance angiogenesis [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Blocking WNT reduces the PDK-1 level via the transcription regulation and reduces in vivo tumor growth [<xref ref-type="bibr" rid="CR35">35</xref>]. Conversely, PPAR gamma activation selectively decreases PDK mRNA [<xref ref-type="bibr" rid="CR68">68</xref>]. PDKs allow metabolic flexibility [<xref ref-type="bibr" rid="CR69">69</xref>] and are transcriptionally regulated by insulin, glucocorticoids, thyroid hormone and fatty acids [<xref ref-type="bibr" rid="CR70">70</xref>]. Several diseases presenting PDK abnormalities are often associated with type 2 diabetes, obesity, metabolic disorders, cardiomyopathies, neuropathies and cancers.</p>
<p>In colon cancer, activation of WNT/beta-catenin signaling decreases the oxidative metabolism in the TCA cycle and promotes cell proliferation [<xref ref-type="bibr" rid="CR35">35</xref>]. In addition, the WNT/beta-catenin pathway induces the transcription of genes involved in cell proliferation, particularly CYCLIN D1 and MYC operating through the G1 phase [<xref ref-type="bibr" rid="CR71">71</xref>–<xref ref-type="bibr" rid="CR74">74</xref>]. MYC activates aerobic glycolysis and glutaminolysis and favors nucleotide synthesis [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. MYC also activates LDH-A, induces glutamine uptake into the cell and mitochondria, and stimulates aspartate synthesis which favors nucleotide synthesis [<xref ref-type="bibr" rid="CR75">75</xref>] (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Moreover, MYC increases the hypoxia-inducible factor -1alpha (HIF1A) which controls PDK-1 [<xref ref-type="bibr" rid="CR77">77</xref>]. Part of the pyruvate is converted into acetyl-CoA which in turn enters the TCA cycle and is converted into citrate. This promotes protein and lipid synthesis. Cellular accumulation of metabolic intermediates (aspartate, serine, glycine, and ribose) allows de novo nucleotide synthesis, which contributes to growth and proliferation.</p>
<p>Phosphofructokinase (PFK), an allosteric enzyme, is responsible for glycolytic oscillations. PFK can lead to instabilities beyond which a new state can be organized in time and in space [<xref ref-type="bibr" rid="CR78">78</xref>]. A positive feedback is responsible for periodic behavior. These far-from-equilibrium oscillatory mechanisms come within the field of dissipative structures initially described by Illia Prigogine [<xref ref-type="bibr" rid="CR79">79</xref>]. Elevated PFK-1 activity is characteristic of cancer cells and is induced in response to oncogenes [<xref ref-type="bibr" rid="CR80">80</xref>].</p>
<p>Cancer cells are characterized by increased glucose consumption. High serum glucose levels may modulate cancer-related processes. Glucose itself can directly impact the canonical WNT pathway [<xref ref-type="bibr" rid="CR81">81</xref>]. High glucose level enhances the nuclear translocation of beta-catenin in response to WNT activation. In cancer cells, glucose-induced beta-catenin acetylation favors the WNT pathway.</p>
</sec>
<sec id="Sec6">
<title>Aerobic glycolysis and vitamin C</title>
<p>It has been recently described a novel antitumoral mechanism of vitamin C [<xref ref-type="bibr" rid="CR82">82</xref>]. Mutation of the proto-oncogene KRAS is often present in colon and pancreatic cancer. In KRAS mutant colorectal cancer, this mechanism involves the Warburg metabolic disruption. In the absence of vitamin C, pyruvate kinase PKM2 is phosphorylated, then translocates to the nucleus and binds the beta-catenin/TCF/LEF transcriptional factor. This promotes the MYC transcription which in turn enhances GLUT-1 and Polypyrimidine Tract Binding Protein (PTB) expression. In the presence of vitamin C which enters into the cell via GLUT-1, RAS is detached from the cell membrane which blocks the PKM2 phosphorylation. This induces downregulation of GLUT-1 and PKM2 expression via disruption of the beta-catenin/TEF/LEF transcriptional complex. This leads to downregulation of MYC and inhibition of the Warburg pathway. Thus, vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer.</p>
</sec>
<sec id="Sec7">
<title>Thermodynamics and lawless-disorderly cancer growth</title>
<p>From a thermodynamic viewpoint, the lawless-disorderly cancer growth and the orderly fetal growth share some similar features [<xref ref-type="bibr" rid="CR83">83</xref>]. Hypoxic conditions reported in cancer cells for their growth requirements resemble to those observed during normal fetal growth, which requires a relatively low oxygen tension. For both cancerous and fetal growth, low energy requirements are linked to the tumorigenic arm of acute inflammation [<xref ref-type="bibr" rid="CR83">83</xref>], as in wound healing. Moreover, the production of lactate under aerobic glycolysis conditions is characteristic of the human placenta [<xref ref-type="bibr" rid="CR84">84</xref>], a tissue in which the population of contractile myofibroblasts is important [<xref ref-type="bibr" rid="CR85">85</xref>]. In cancer (mammary carcinoma, epithelial cells in cancerous mammary glands), fibrotic lesions (Dupuytrens nodules, hypertrophic scars) [<xref ref-type="bibr" rid="CR86">86</xref>], and normal placental stem villi [<xref ref-type="bibr" rid="CR87">87</xref>], the main myosin molecular motor in myofibroblasts is the non muscle myosin (NMM). Kinetics of contractile NMM crossbridges are dramatically slow [<xref ref-type="bibr" rid="CR88">88</xref>] and their entropy production rate is extremely low [<xref ref-type="bibr" rid="CR89">89</xref>]. The presence of numerous myofibroblasts is associated with the aerobic glycolysis metabolism. In epithelial cancers, myofibroblasts represent a significant part of the stroma reaction. Myofibroblasts, epithelial cells, and connective tissue cells participate to cancer invasion, with loss of epithelial characteristics and acquisition of mesenchymal properties. This refers to as EMT [<xref ref-type="bibr" rid="CR26">26</xref>] which greatly influences the invasive carcinoma progression and in which the canonical WNT pathway plays a key role. WNT3a favors myofibroblast differentiation by upregulating the transforming growth factor (TGF-beta1). This occurs through SMAD2 in a beta-catenin-dependent manner [<xref ref-type="bibr" rid="CR90">90</xref>]. Importantly, it has been recently demonstrated that aerobic glycolysis is induced in response to TGF-beta1 [<xref ref-type="bibr" rid="CR91">91</xref>].</p>
</sec>
<sec id="Sec8">
<title>Activation of WNT/beta-catenin pathway and inactivation of PPAR gamma in cancers</title>
<p>WNT/beta-catenin signaling has been found to be activated in cancers [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. WNT1 was first discovered as a proto-oncogene in a breast cancer mouse model. Increased expression of beta-catenin may be due to factors such as mutations in beta-catenin, abnormalities in the beta-catenin destruction complex, mutations in APC, overexpression of WNT ligands, and loss of inhibition or decreased activity of regulatory pathways. Alterations in gene expression of <italic>CTNNB1</italic> which encodes beta-catenin, have been reported in numerous cancers such as breast colorectal, melanoma, prostate and lung tumors. WNT 1, WNT2 and WNT7A ligand-proteins are overexpressed in glioblastoma, esophageal cancer and ovarian cancer respectively. Proteins of the TCF/LEF family and WNT5A may also induce cancer. Repression of WNT/beta-catenin signaling can prevent EMT and inhibit metastasis. Mutations of the WNT pathway components are associated with many cancers, particularly with colorectal cancer. APC deficiency and beta-catenin mutations upregulate the WNT/beta-catenin pathway and prevent beta-catenin degradation. This leads to excessive stem cell renewal and cell proliferation that predisposes to tumor genesis particularly for colorectal cancer [<xref ref-type="bibr" rid="CR94">94</xref>]. Nuclear accumulation of beta-catenin drives cancer cell proliferation. In colon cancer, beta-catenin-TCF/LEF signaling is activated [<xref ref-type="bibr" rid="CR95">95</xref>], and activation of the WNT pathway via <italic>APC</italic> gene mutations favors cell proliferation [<xref ref-type="bibr" rid="CR96">96</xref>]. Mutations in PPAR gamma are linked with human colon cancer [<xref ref-type="bibr" rid="CR97">97</xref>].</p>
<p>Several studies have presented evidence for a protective role of PPAR gamma against cancer. In colon cancer, PPAR gamma downregulates the oncogene beta-catenin and suppresses cell proliferation [<xref ref-type="bibr" rid="CR98">98</xref>]. In contrast, other studies have implicated PPAR gamma in the promotion and development of cancer [<xref ref-type="bibr" rid="CR8">8</xref>]. Thus, PPAR gamma activation by specific agonists can induce growth inhibition, apoptosis and differentiation of numerous tumor cells. On the contrary, overexpression of PPAR gamma has been reported in tumors of colon, breast, prostate, stomach, salivary gland, cervix, ovary, bladder, lung, testes and the neural crest element of sympathetic nervous system [<xref ref-type="bibr" rid="CR7">7</xref>]. The biological significance of PPAR gamma in cancer remains controversial. Activation of PPAR gamma can induce either tumor suppressive or promoting responses. On the one hand, PPAR gamma can act as a tumor inhibitor in colon cancer [<xref ref-type="bibr" rid="CR99">99</xref>–<xref ref-type="bibr" rid="CR105">105</xref>], in breast cancer [<xref ref-type="bibr" rid="CR106">106</xref>–<xref ref-type="bibr" rid="CR110">110</xref>], in urological cancer [<xref ref-type="bibr" rid="CR110">110</xref>–<xref ref-type="bibr" rid="CR115">115</xref>], in lung cancer [<xref ref-type="bibr" rid="CR116">116</xref>–<xref ref-type="bibr" rid="CR118">118</xref>], and in gastric cancer [<xref ref-type="bibr" rid="CR119">119</xref>–<xref ref-type="bibr" rid="CR122">122</xref>]. On the other hand, PPAR gamma can act as a tumor promotor in colon cancer [<xref ref-type="bibr" rid="CR123">123</xref>–<xref ref-type="bibr" rid="CR126">126</xref>], in breast cancer [<xref ref-type="bibr" rid="CR127">127</xref>–<xref ref-type="bibr" rid="CR132">132</xref>], and in urological cancer [<xref ref-type="bibr" rid="CR133">133</xref>–<xref ref-type="bibr" rid="CR135">135</xref>]. There is no clear unifying accepted mechanism explaining these contradictory evidences concerning either the protective role of PPAR gamma or their role on promotion/development of cancer. This might be partly explained by cell type-specific effects, organ-specific effects, receptor-independent effects according to the PPAR gamma agonist used. This might also be due to specific pharmacokinetic properties of PPAR gamma ligands or the stage of cancer development at which the PPAR gamma ligand is administered [<xref ref-type="bibr" rid="CR8">8</xref>]. These arguments are hypotheses, and for the time being, no universal mechanism is able to explain the contradictory effects of PPAR gamma ligands on cancers.</p>
</sec>
<sec id="Sec9">
<title>Role of PI3K-AKT pathway in aerobic glycolysis and cancers</title>
<p>Hyperactivation of phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT) pathway is associated with an increased rate of glucose metabolism in tumor cells [<xref ref-type="bibr" rid="CR136">136</xref>]. AKT signaling directly acts on aerobic glycolysis in cancer cells. AKT regulates the localization of GLUT1 in the plasma membrane and hexokinase expression. It also activates phosphofructokinase-1 (PFK-1) which directly phosphorylates PFK-2. This leads to produce fructose-2.6-bisphosphate, an activator of PFK-1. AKT activation causes an increase in aerobic glycolysis or Warburg effect in cancer. PI3K-AKT pathway promotes cell survival, cell growth, cell proliferation, cell migration and angiogenesis in response to extracellular signals including hormones and growth factors. This pathway is stimulated by the binding of extracellular ligands to a receptor tyrosine kinase (RTK) located in the plasma membrane (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). This signaling is upregulated in certain cancers. Through phosphorylation of GSK-3beta, PI3 K-AKT favors the G1 phase of the cell cycle. GSK-3beta phosphorylation decreases the degradation of beta-catenin in the proteasome. Thus, TCF/LEF transcription factor is activated which in turn favors transcription of the target gene CYCLIN D1 [<xref ref-type="bibr" rid="CR137">137</xref>]. Consequently, by decreasing the GSK-3beta activity, AKT pathway behaves similarly to the WNT pathway. Aberrant activation of PI3K-AKT is often associated with cancers, including glioblastomas, ovarian, pancreatic and breast cancers [<xref ref-type="bibr" rid="CR138">138</xref>]. AKT mRNA is increased in breast and prostate cancer. PI3K-AKT contributes to angiogenesis by acting on the vascular endothelial growth factor in endothelial cells and on the endothelial nitric oxide synthase. This activates vasodilation and vascular remodeling [<xref ref-type="bibr" rid="CR139">139</xref>]. Moreover, the PI3K-AKT pathway increases the hypoxia-inducible transcription factor [<xref ref-type="bibr" rid="CR140">140</xref>].</p>
<p>The phosphatase and tensin homologue (PTEN) represents the main brake of the PI 3′-OH kinase (PIK3)-AKT pathway [<xref ref-type="bibr" rid="CR141">141</xref>]. PI3K generate phosphatidylinositol-3,4,5-triphosphate (PIP3) from PIP2. AKT is activated by PIP3. PTEN is a PIP3-phosphatase and its activity is opposed to that of PI3K. PI3K-AKT signaling is a major pathway which is activated in cancer. PTEN appears to be relevant against cancer progression and represents a target for somatic cancer inactivation. In some cancers (endometrial, breast, and colorectal cancers), PI3K and PTEN mutations coexist. PTEM also induces a decrease in cancer cell proliferation due to cell cycle arrest in the G1 phase.</p>
</sec>
<sec id="Sec10">
<title>Prostaglandins, WNT and PPAR gamma</title>
<p>Several studies have established the role of prostaglandin E2 (PGE2) by activating the WNT/beta-catenin pathway. The link between PGE2 and the canonical WNT pathway suggests that chronic inflammation induced by a prolonged increase of PGE2 could lead to activation of WNT signaling resulting in cell proliferation and cancer. PGE2 enhances the beta-catenin-dependent transcription [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR143">143</xref>]. PGE2 promotes colon cancer cell growth through the beta-catenin pathway. Thus, blockage of WNT/beta-catenin signaling can be of interest for cancer treatment. In treatment of colorectal cancer, nonsteroidal anti-inflammatory drugs (NSAIDs) induce beneficial effects [<xref ref-type="bibr" rid="CR144">144</xref>], partly due to their interaction with the beta-catenin pathway and their inhibition of the PGE2 synthesis. PGE2 modulates the WNT activity in hematopoietic stem cell (HSC) in zebrafish. Inhibition of PGE2 synthesis blocks alterations in HSC induced by WNT. PGE2 modifies the WNT signaling cascade at the level of beta-catenin degradation through the cAMP/PKA pathway. WNT activation in stem cells requires PGE2 [<xref ref-type="bibr" rid="CR145">145</xref>]. Dimethyl-prostaglandin E2 increases HSC in vivo. In addition, dimethyl-prostaglandin E2 leads to the formation of components of the WNT pathway [<xref ref-type="bibr" rid="CR146">146</xref>]. WNT signaling upregulates interleukin (IL)-7R and IL-2Rbeta. In neuroectodermal (NE-4C) stem cells, PGE2 interacts with the canonical WNT signaling through PKA and PI3K [<xref ref-type="bibr" rid="CR147">147</xref>]. In WNT-induced cells, beta-catenin is increased and the WNT-target genes (<italic>Ctnnb1</italic>, <italic>Ptgs2</italic>, <italic>Ccnd1</italic>, <italic>Mmp9</italic>) are significantly upregulated after PGE2 use. PPAR gamma and proinflammatory enzyme pathways are interrelated. Decreased expression of PPAR gamma and high levels of COX-2 have been reported in many cancers [<xref ref-type="bibr" rid="CR148">148</xref>]. TZDs decrease COX-2, inhibit growth of non-small-cell lung cancer cells in vitro, and block tumor development. TZDs diminish COX-2 and PGE2 through PPAR gamma. The PPAR gamma activator 15dPGJ2 plays an anti-inflammatory role in a PPAR gamma-dependent manner, decreasing COX-2, PGE2 and iNos expression [<xref ref-type="bibr" rid="CR149">149</xref>].</p>
</sec>
<sec id="Sec11">
<title>Circadian rhythms (CRs), cancers, metabolism and thermodynamics</title>
<p>CRs can be defined as endogenous, entrainable free-running periods that last approximately 24 h. CRs are far-from-equilibrium dissipative structures and are due to a negative feedback produced by a protein on the expression of its own gene [<xref ref-type="bibr" rid="CR150">150</xref>–<xref ref-type="bibr" rid="CR152">152</xref>]. They operate in far-from-equilibrium manner if affinity of the studied system is ≫RT (R is the universal gas constant and T is the absolute temperature), and generate order spontaneously by exchanging energy with their external environment [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. In mammals, CRs involve several major critical transcription factors such as circadian locomotor output cycles kaput (CLOCK), brain and muscle aryl-hydrocarbon receptor nuclear translocator-like1 (BMAL1), period 1 (PER1), period 2 (PER2), and period 3 (PER3) [<xref ref-type="bibr" rid="CR154">154</xref>, <xref ref-type="bibr" rid="CR155">155</xref>]. Transcription/translation autoregulatory feedback loops with both activating and inhibiting pathways are involved in CRs [<xref ref-type="bibr" rid="CR156">156</xref>, <xref ref-type="bibr" rid="CR157">157</xref>].</p>
<p>Circadian rhythms govern numerous physiological and metabolic functions [<xref ref-type="bibr" rid="CR158">158</xref>]. Thus, CRs are observed in sleep-awake and feeding patterns, energy metabolism, body temperature, hormone secretion, heart rate and blood pressure. Following epidemioloigical and genetic probes, it has been suggested that disruption of CRs may be directly linked to cancer, leading to aberrant cellular proliferation [<xref ref-type="bibr" rid="CR159">159</xref>]. Since numerous connections between the circadian clock and cellular metabolism have been reported, it is thougth that the abnormal metabolism observed in cancer may be a consequence of disrupted CRs. CRs within the cell regulate the timing of many important life cycles [<xref ref-type="bibr" rid="CR160">160</xref>]. The phase diffusion constant depends on the free-energy dissipation per period. Oscillations are driven by multiple irreversible cycles that hydrolyze fuel molecules such as ATP. The free energy consumed per period is proportional to the number of phase coherent periods. A decreased <italic>BMAL1</italic> function modifies the behavior of genes involved in the canonical WNT pathway [<xref ref-type="bibr" rid="CR161">161</xref>]. Beta-catenin induces PER2 degradation altering circadian clock gene in intestinal mucosa of ApcMin/+ mice [<xref ref-type="bibr" rid="CR162">162</xref>]. A deceased expression level of PER1 and/or PER2 has been reported in numerous cancers: breast cancer [<xref ref-type="bibr" rid="CR163">163</xref>], prostate cancer [<xref ref-type="bibr" rid="CR164">164</xref>], pancreatic cancer [<xref ref-type="bibr" rid="CR165">165</xref>], colorectal cancer [<xref ref-type="bibr" rid="CR166">166</xref>], chronic myeloid leukemia [<xref ref-type="bibr" rid="CR167">167</xref>], and glioma [<xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR169">169</xref>].</p>
<p>Peroxisome proliferator-activated receptors interferes with the mammalian clock and energy metabolism [<xref ref-type="bibr" rid="CR170">170</xref>]. PPARs are rhythmically expressed in mammalian tissues [<xref ref-type="bibr" rid="CR171">171</xref>] and directly interact with the core clock genes. PPAR gamma exhibits variations in diurnal expression in mouse fat, liver and blood vessels [<xref ref-type="bibr" rid="CR42">42</xref>]. Deletion of <italic>PPAR gamma</italic> in mouse impairs diurnal rhythms [<xref ref-type="bibr" rid="CR172">172</xref>]. PPAR gamma plays an important role in the coordinated control of circadian clocks, metabolism and cardiac performance. PGC-1 alpha, a transcriptional co-activator that regulates energy metabolism, is rhythmically expressed in the liver and skeletal muscle of mice. PGC-1 alpha upregulates the expression of the clock genes <italic>BMAL1</italic> and <italic>Rev</italic>-<italic>erb alpha</italic>. Mice lacking PGC-1 alpha show changes in CRs and metabolism [<xref ref-type="bibr" rid="CR173">173</xref>]. PGC-1 alpha acts as a stress sensor in cancer cells. In maintaining metabolic homeostasis, PGC-1 alpha favors cancer cell survival [<xref ref-type="bibr" rid="CR174">174</xref>]. PGC-1 alpha interfers in a very complex manner with nuclear receptors such as Rev-erb, ROR, PPARs [<xref ref-type="bibr" rid="CR175">175</xref>]. PPAR alpha and gamma up-regulate the expression of Rev-erb alpha and BMAL1 by binding to their promotors. PGC-1 potentiates ROR alpha transcriptional activity and enhances both Rev-erb alpha and BMAL1 transcription. Moreover after serum shock, GSK-3beta-mediated stabilization of Rev-erb alpha plays a key role to initiate, maintain and synchronize CRs.</p>
</sec>
</sec>
<sec id="Sec12">
<title>Conclusions</title>
<p>Cancers exhibit thermodynamic and metabolic alterations and abnormal CRs. In many cancers but not all, the canonical WNT/beta-catenin pathway is upregulated, while PPAR gamma is downregulated, the two systems behaving in an opposite manner. Overactivation of the WNT pathway results in cell proliferation due to the activation of certain target genes of beta-catenin, such as MYC and CYCLIN D1. This promotes protein synthesis and angiogenesis. <italic>PDK</italic> and <italic>MCT</italic>-<italic>1</italic> are also target genes of beta-catenin, explaining the significant decrease in the transformation of pyruvate into acetyl-CoA in mitochondria and the formation of intracellular lactate, which will be extruded out of the cell. This is referred to as aerobic glycolysis or the Warburg phenomenon. The expression of PPAR gamma is decreased due to the overactivation of WNT/beta-catenin signaling. Circadian rhythms, dissipative structures which are governed by the laws of far-from-equilibrium thermodynanics are disrupted in cancers. They are influenced by both the WNT/beta-catenin pathway and PPAR gamma. Changes in thermodynamics, metabolism and circadian rhythms are tightly linked in cancers.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>acetyl-CoA</term>
<def>
<p>acetyl-coenzyme A</p>
</def>
</def-item>
<def-item>
<term>APC</term>
<def>
<p>adenomatous polyposis coli</p>
</def>
</def-item>
<def-item>
<term>ARVC</term>
<def>
<p>arrhythmogenic right ventricular dysplasia/cardiomyopathy</p>
</def>
</def-item>
<def-item>
<term>BMAL1</term>
<def>
<p>brain and muscle aryl-hydrocarbon receptor nuclear translocator-like1</p>
</def>
</def-item>
<def-item>
<term>CLOCK</term>
<def>
<p>circadian locomotor output cycles kaput</p>
</def>
</def-item>
<def-item>
<term>COX-2</term>
<def>
<p>cyclooxygenase-2</p>
</def>
</def-item>
<def-item>
<term>DSH</term>
<def>
<p>dishevelled</p>
</def>
</def-item>
<def-item>
<term>EMT</term>
<def>
<p>epithelial-mesenchymal transition</p>
</def>
</def-item>
<def-item>
<term>FZD</term>
<def>
<p>frizzled</p>
</def>
</def-item>
<def-item>
<term>GK</term>
<def>
<p>glucokinase</p>
</def>
</def-item>
<def-item>
<term>GLUT</term>
<def>
<p>glucose transporter</p>
</def>
</def-item>
<def-item>
<term>GSK-3beta</term>
<def>
<p>glycogen synthase kinase-3beta</p>
</def>
</def-item>
<def-item>
<term>HSC</term>
<def>
<p>hematopoietic stem cell</p>
</def>
</def-item>
<def-item>
<term>LDH</term>
<def>
<p>lactate dehydrogenase</p>
</def>
</def-item>
<def-item>
<term>LRP5/6</term>
<def>
<p>low-density lipoprotein receptor-related protein 5/6</p>
</def>
</def-item>
<def-item>
<term>MCT-1</term>
<def>
<p>monocarboxylate lactate transporter-1</p>
</def>
</def-item>
<def-item>
<term>NSAID</term>
<def>
<p>nonsteroidal anti-inflammatory drug</p>
</def>
</def-item>
<def-item>
<term>PER</term>
<def>
<p>period</p>
</def>
</def-item>
<def-item>
<term>PPAR</term>
<def>
<p>peroxisome proliferator-activated receptor</p>
</def>
</def-item>
<def-item>
<term>PGC-1 alpha</term>
<def>
<p>peroxisome proliferator-activated receptor-gamma coactivator-1 alpha</p>
</def>
</def-item>
<def-item>
<term>PI3K-AKT</term>
<def>
<p>phosphatidylinositol 3-kinase-protein kinase B</p>
</def>
</def-item>
<def-item>
<term>PFK-1</term>
<def>
<p>phosphofructokinase-1</p>
</def>
</def-item>
<def-item>
<term>PGE2</term>
<def>
<p>prostaglandin E2</p>
</def>
</def-item>
<def-item>
<term>PDH</term>
<def>
<p>pyruvate dehydrogenase complex</p>
</def>
</def-item>
<def-item>
<term>PDK</term>
<def>
<p>pyruvate dehydrogenase kinase</p>
</def>
</def-item>
<def-item>
<term>RTK</term>
<def>
<p>receptor tyrosine kinase</p>
</def>
</def-item>
<def-item>
<term>TCF/LEF</term>
<def>
<p>T cell factor factor/lymphoid enhancer factor</p>
</def>
</def-item>
<def-item>
<term>TZD</term>
<def>
<p>thiazolidinedione</p>
</def>
</def-item>
<def-item>
<term>TGF-beta1</term>
<def>
<p>transforming growth factor</p>
</def>
</def-item>
<def-item>
<term>TCA</term>
<def>
<p>tricarboxylic acid</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Authors’ contributions</title>
<p>YL, VC, AV and J-LH have contributed equally to this review. All authors read and approved the final manuscript.</p>
<sec id="FPar1">
<title>Acknowledgements</title>
<p>We would like to thank Dr. Christophe Locher, President of the “Fédération de la Recherche Clinique du Grand Hôpital de l’Est Francilien”, and Mr. Vincent Gobert, Administrative Manager of the Clinical Research Center, Meaux Hospital, Meaux, France, for their valuable support in making the necessary research facilities available for this study. The manuscript has been revised by Brian Keogh, Ph.D.</p>
</sec>
<sec id="FPar2">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar3">
<title>Publisher’s Note</title>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<mixed-citation publication-type="other">Schrödinger E (1944) What is life?: Cambridge University Press, Cambridge</mixed-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prigogine</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nicolis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Babloyantz</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Nonequilibrium problems in biological phenomena</article-title>
<source/>Ann NY Acad Sci
          <year>1974</year>
<volume>231</volume>
<fpage>99</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.1974.tb20557.x</pub-id>
<pub-id pub-id-type="pmid">4522899</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prigogine</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Life and physics. New perspectives</article-title>
<source/>Cell Biophys
          <year>1986</year>
<volume>9</volume>
<fpage>217</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1007/BF02797383</pub-id>
<pub-id pub-id-type="pmid">2436795</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Atkins</surname>
<given-names>PW</given-names>
</name>
</person-group>
<source/>Physical chemistry
          <year>1990</year>
<publisher-loc>Oxford</publisher-loc>
<publisher-name>Oxford University Press</publisher-name>
<fpage>1</fpage>
<lpage>1031</lpage>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Kondepudi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Prigogine</surname>
<given-names>I</given-names>
</name>
</person-group>
<source/>Modern thermodynamics from heat engines to dissipative structures
          <year>1999</year>
<publisher-loc>New York</publisher-loc>
<publisher-name>Wiley</publisher-name>
<fpage>1</fpage>
<lpage>486</lpage>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Duthoit</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hebert</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction</article-title>
<source/>Front Physiol
          <year>2014</year>
<volume>5</volume>
<fpage>429</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2014.00429</pub-id>
<pub-id pub-id-type="pmid">25414671</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Pillai</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Biology of PPAR gamma in cancer: a critical review on existing lacunae</article-title>
<source/>Curr Mol Med
          <year>2007</year>
<volume>7</volume>
<fpage>532</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="doi">10.2174/156652407781695765</pub-id>
<pub-id pub-id-type="pmid">17896990</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youssef</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Badr</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptors and cancer: challenges and opportunities</article-title>
<source/>Br J Pharmacol
          <year>2011</year>
<volume>164</volume>
<fpage>68</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01383.x</pub-id>
<pub-id pub-id-type="pmid">21449912</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vallee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hébert</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Interactions between PPAR gamma and the canonical Wnt/beta-catenin pathway in type 2 diabetes and colon cancer</article-title>
<source/>PPAR Res
          <year>2017</year>
<volume>5</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1155/2017/5879090</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Vallee</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Opposite interplay between PPAR gamma and canonical Wnt/Beta-catenin pathway in amyotrophic lateral sclerosis</article-title>
<source/>Front Neurol
          <year>2016</year>
<volume>7</volume>
<fpage>100</fpage>
<pub-id pub-id-type="doi">10.3389/fneur.2016.00100</pub-id>
<pub-id pub-id-type="pmid">27445967</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Godin</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Poizat</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hickey</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Maschat</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Humbert</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington’s disease</article-title>
<source/>EMBO J
          <year>2010</year>
<volume>29</volume>
<fpage>2433</fpage>
<lpage>2445</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2010.117</pub-id>
<pub-id pub-id-type="pmid">20531388</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drew</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Racke</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>PPAR-gamma: therapeutic potential for multiple sclerosis</article-title>
<source/>PPAR Res
          <year>2008</year>
<volume>2008</volume>
<fpage>627463</fpage>
<pub-id pub-id-type="doi">10.1155/2008/627463</pub-id>
<pub-id pub-id-type="pmid">18604287</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Wnt signaling in the pathogenesis of multiple sclerosis-associated chronic pain</article-title>
<source/>J Neuroimmune Pharmacol
          <year>2012</year>
<volume>7</volume>
<fpage>904</fpage>
<lpage>913</lpage>
<pub-id pub-id-type="doi">10.1007/s11481-012-9370-3</pub-id>
<pub-id pub-id-type="pmid">22547300</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Marmolino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Cnop</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich’s ataxia</article-title>
<source/>Hum Mol Genet
          <year>2009</year>
<volume>18</volume>
<fpage>2452</fpage>
<lpage>2461</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddp183</pub-id>
<pub-id pub-id-type="pmid">19376812</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Gras</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Giocondo</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Willerson</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>MD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy</article-title>
<source/>J Clin Invest
          <year>2006</year>
<volume>116</volume>
<fpage>2012</fpage>
<lpage>2021</lpage>
<pub-id pub-id-type="doi">10.1172/JCI27751</pub-id>
<pub-id pub-id-type="pmid">16823493</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Djouadi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hebert</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Charron</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bastin</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy</article-title>
<source/>Cardiovasc Res
          <year>2009</year>
<volume>84</volume>
<fpage>83</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1093/cvr/cvp183</pub-id>
<pub-id pub-id-type="pmid">19497962</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canalis</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches</article-title>
<source/>Nat Rev Endocrinol
          <year>2013</year>
<volume>9</volume>
<fpage>575</fpage>
<lpage>583</lpage>
<pub-id pub-id-type="doi">10.1038/nrendo.2013.154</pub-id>
<pub-id pub-id-type="pmid">23938284</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rawadi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Roman-Roman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Wnt signalling pathway: a new target for the treatment of osteoporosis</article-title>
<source/>Expert Opin Ther Targets
          <year>2005</year>
<volume>9</volume>
<fpage>1063</fpage>
<lpage>1077</lpage>
<pub-id pub-id-type="doi">10.1517/14728222.9.5.1063</pub-id>
<pub-id pub-id-type="pmid">16185158</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korvala</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Juppner</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Makitie</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Sochett</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schnabel</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity</article-title>
<source/>BMC Med Genet
          <year>2012</year>
<volume>13</volume>
<fpage>26</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2350-13-26</pub-id>
<pub-id pub-id-type="pmid">22487062</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallee</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Alzheimer disease: crosstalk between the canonical Wnt/beta-catenin pathway and PPARs alpha and gamma</article-title>
<source/>Front Neurosci
          <year>2016</year>
<volume>10</volume>
<fpage>459</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00459</pub-id>
<pub-id pub-id-type="pmid">27807401</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berwick</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The importance of Wnt signalling for neurodegeneration in Parkinson’s disease</article-title>
<source/>Biochem Soc Trans
          <year>2012</year>
<volume>40</volume>
<fpage>1123</fpage>
<lpage>1128</lpage>
<pub-id pub-id-type="doi">10.1042/BST20120122</pub-id>
<pub-id pub-id-type="pmid">22988876</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gould</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Manji</surname>
<given-names>HK</given-names>
</name>
</person-group>
<article-title>The Wnt signaling pathway in bipolar disorder</article-title>
<source/>Neuroscientist
          <year>2002</year>
<volume>8</volume>
<fpage>497</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="doi">10.1177/107385802237176</pub-id>
<pub-id pub-id-type="pmid">12374432</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valvezan</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>PS</given-names>
</name>
</person-group>
<article-title>GSK-3 and Wnt signaling in neurogenesis and bipolar disorder</article-title>
<source/>Front Mol Neurosci
          <year>2012</year>
<volume>5</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2012.00001</pub-id>
<pub-id pub-id-type="pmid">22319467</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panaccione</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Napoletano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Forte</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Kotzalidis</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Del Casale</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurodevelopment in schizophrenia: the role of the wnt pathways</article-title>
<source/>Curr Neuropharmacol
          <year>2013</year>
<volume>11</volume>
<fpage>535</fpage>
<lpage>558</lpage>
<pub-id pub-id-type="doi">10.2174/1570159X113119990037</pub-id>
<pub-id pub-id-type="pmid">24403877</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Krokidis</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pineau</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hebert</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased entropy production in diaphragm muscle of PPAR alpha knockout mice</article-title>
<source/>J Theor Biol
          <year>2008</year>
<volume>250</volume>
<fpage>92</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1016/j.jtbi.2007.09.022</pub-id>
<pub-id pub-id-type="pmid">17980390</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heuberger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Birchmeier</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Interplay of cadherin-mediated cell adhesion and canonical wnt signaling</article-title>
<source/>Cold Spring Harb Perspect Biol
          <year>2010</year>
<volume>2</volume>
<fpage>a002915</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a002915</pub-id>
<pub-id pub-id-type="pmid">20182623</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Igota</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tosa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Egawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification and characterization of Wnt signaling pathway in keloid pathogenesis</article-title>
<source/>Int J Med Sci
          <year>2013</year>
<volume>10</volume>
<fpage>344</fpage>
<lpage>354</lpage>
<pub-id pub-id-type="doi">10.7150/ijms.5349</pub-id>
<pub-id pub-id-type="pmid">23471552</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moon</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Bowerman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Boutros</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Perrimon</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>The promise and perils of Wnt signaling through beta-catenin</article-title>
<source/>Science
          <year>2002</year>
<volume>296</volume>
<fpage>1644</fpage>
<lpage>1646</lpage>
<pub-id pub-id-type="doi">10.1126/science.1071549</pub-id>
<pub-id pub-id-type="pmid">12040179</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moon</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Kohn</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>De Ferrari</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Kaykas</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>WNT and beta-catenin signalling: diseases and therapies</article-title>
<source/>Nat Rev Genet
          <year>2004</year>
<volume>5</volume>
<fpage>691</fpage>
<lpage>701</lpage>
<pub-id pub-id-type="doi">10.1038/nrg1427</pub-id>
<pub-id pub-id-type="pmid">15372092</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nusse</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Wnt signaling in disease and in development</article-title>
<source/>Cell Res
          <year>2005</year>
<volume>15</volume>
<fpage>28</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1038/sj.cr.7290260</pub-id>
<pub-id pub-id-type="pmid">15686623</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clevers</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Wnt/beta-catenin signaling in development and disease</article-title>
<source/>Cell
          <year>2006</year>
<volume>127</volume>
<fpage>469</fpage>
<lpage>480</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.10.018</pub-id>
<pub-id pub-id-type="pmid">17081971</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Sparks</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Rago</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hermeking</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zawel</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of c-MYC as a target of the APC pathway</article-title>
<source/>Science
          <year>1998</year>
<volume>281</volume>
<fpage>1509</fpage>
<lpage>1512</lpage>
<pub-id pub-id-type="doi">10.1126/science.281.5382.1509</pub-id>
<pub-id pub-id-type="pmid">9727977</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shtutman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhurinsky</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Simcha</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Albanese</surname>
<given-names>C</given-names>
</name>
<name>
<surname>D’Amico</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway</article-title>
<source/>Proc Natl Acad Sci USA
          <year>1999</year>
<volume>96</volume>
<fpage>5522</fpage>
<lpage>5527</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.96.10.5522</pub-id>
<pub-id pub-id-type="pmid">10318916</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>RT</given-names>
</name>
</person-group>
<article-title>Proximal events in Wnt signal transduction</article-title>
<source/>Nat Rev Mol Cell Biol
          <year>2009</year>
<volume>10</volume>
<fpage>468</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2674</pub-id>
<pub-id pub-id-type="pmid">19536106</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pate</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Stringari</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sprowl-Tanio</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>TeSlaa</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer</article-title>
<source/>EMBO J
          <year>2014</year>
<volume>33</volume>
<fpage>1454</fpage>
<lpage>1473</lpage>
<pub-id pub-id-type="pmid">24825347</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tyagi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Saini</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Kaushal</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases</article-title>
<source/>J Adv Pharm Technol Res
          <year>2011</year>
<volume>2</volume>
<fpage>236</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.4103/2231-4040.90879</pub-id>
<pub-id pub-id-type="pmid">22247890</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elbrecht</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Cullinan</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Leibowitz</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2</article-title>
<source/>Biochem Biophys Res Commun
          <year>1996</year>
<volume>224</volume>
<fpage>431</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.1996.1044</pub-id>
<pub-id pub-id-type="pmid">8702406</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fajas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Auboeuf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Raspe</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schoonjans</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lefebvre</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The organization, promoter analysis, and expression of the human PPAR gamma gene</article-title>
<source/>J Biol Chem
          <year>1997</year>
<volume>272</volume>
<fpage>18779</fpage>
<lpage>18789</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.272.30.18779</pub-id>
<pub-id pub-id-type="pmid">9228052</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desvergne</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wahli</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptors: nuclear control of metabolism</article-title>
<source/>Endocr Rev
          <year>1999</year>
<volume>20</volume>
<fpage>649</fpage>
<lpage>688</lpage>
<pub-id pub-id-type="pmid">10529898</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rangwala</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lazar</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptor gamma in diabetes and metabolism</article-title>
<source/>Trends Pharmacol Sci
          <year>2004</year>
<volume>25</volume>
<fpage>331</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2004.03.012</pub-id>
<pub-id pub-id-type="pmid">15165749</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picard</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Auwerx</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>PPAR(gamma) and glucose homeostasis</article-title>
<source/>Annu Rev Nutr
          <year>2002</year>
<volume>22</volume>
<fpage>167</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.nutr.22.010402.102808</pub-id>
<pub-id pub-id-type="pmid">12055342</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Aoyagi</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1</article-title>
<source/>Cell Metab
          <year>2008</year>
<volume>8</volume>
<fpage>482</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2008.10.009</pub-id>
<pub-id pub-id-type="pmid">19041764</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hebert</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>PPARs, cardiovascular metabolism, and function: near- or far-from-equilibrium pathways</article-title>
<source/>PPAR Res
          <year>2010</year>
<pub-id pub-id-type="pmid">20706650</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmadian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hah</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Liddle</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Atkins</surname>
<given-names>AR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PPARgamma signaling and metabolism: the good, the bad and the future</article-title>
<source/>Nat Med
          <year>2013</year>
<volume>19</volume>
<fpage>557</fpage>
<lpage>566</lpage>
<pub-id pub-id-type="doi">10.1038/nm.3159</pub-id>
<pub-id pub-id-type="pmid">23652116</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerhold</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists</article-title>
<source/>Endocrinology
          <year>2002</year>
<volume>143</volume>
<fpage>2106</fpage>
<lpage>2118</lpage>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girnun</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Domann</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter</article-title>
<source/>Mol Endocrinol
          <year>2002</year>
<volume>16</volume>
<fpage>2793</fpage>
<lpage>2801</lpage>
<pub-id pub-id-type="doi">10.1210/me.2002-0020</pub-id>
<pub-id pub-id-type="pmid">12456800</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pradeep</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rana</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rana</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway</article-title>
<source/>J Biol Chem
          <year>2004</year>
<volume>279</volume>
<fpage>35583</fpage>
<lpage>35594</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M403143200</pub-id>
<pub-id pub-id-type="pmid">15190077</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takada</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kouzmenko</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis</article-title>
<source/>Nat Rev Rheumatol
          <year>2009</year>
<volume>5</volume>
<fpage>442</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="doi">10.1038/nrrheum.2009.137</pub-id>
<pub-id pub-id-type="pmid">19581903</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Carson</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Repression of beta-catenin signaling by PPAR gamma ligands</article-title>
<source/>Eur J Pharmacol
          <year>2010</year>
<volume>636</volume>
<fpage>198</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2010.03.010</pub-id>
<pub-id pub-id-type="pmid">20303941</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>SR</given-names>
</name>
</person-group>
<article-title>Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin</article-title>
<source/>Mol Cell Biol
          <year>2006</year>
<volume>26</volume>
<fpage>5827</fpage>
<lpage>5837</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.00441-06</pub-id>
<pub-id pub-id-type="pmid">16847334</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moldes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>BH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis</article-title>
<source/>Biochem J
          <year>2003</year>
<volume>376</volume>
<fpage>607</fpage>
<lpage>613</lpage>
<pub-id pub-id-type="doi">10.1042/bj20030426</pub-id>
<pub-id pub-id-type="pmid">12954078</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>Wnt meets Warburg: another piece in the puzzle?</article-title>
<source/>EMBO J
          <year>2014</year>
<volume>33</volume>
<fpage>1420</fpage>
<lpage>1422</lpage>
<pub-id pub-id-type="pmid">24843042</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bienz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Clevers</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Linking colorectal cancer to Wnt signaling</article-title>
<source/>Cell
          <year>2000</year>
<volume>103</volume>
<fpage>311</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)00122-7</pub-id>
<pub-id pub-id-type="pmid">11057903</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brabletz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hlubek</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Spaderna</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schmalhofer</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hiendlmeyer</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal–epithelial transition, stem cells and beta-catenin</article-title>
<source/>Cells Tissues Organs
          <year>2005</year>
<volume>179</volume>
<fpage>56</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1159/000084509</pub-id>
<pub-id pub-id-type="pmid">15942193</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klaus</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Birchmeier</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Wnt signalling and its impact on development and cancer</article-title>
<source/>Nat Rev Cancer
          <year>2008</year>
<volume>8</volume>
<fpage>387</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1038/nrc2389</pub-id>
<pub-id pub-id-type="pmid">18432252</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clevers</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nusse</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Wnt/beta-catenin signaling and disease</article-title>
<source/>Cell
          <year>2012</year>
<volume>149</volume>
<fpage>1192</fpage>
<lpage>1205</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2012.05.012</pub-id>
<pub-id pub-id-type="pmid">22682243</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warburg</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>On the origin of cancer cells</article-title>
<source/>Science
          <year>1956</year>
<volume>123</volume>
<fpage>309</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1126/science.123.3191.309</pub-id>
<pub-id pub-id-type="pmid">13298683</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinheiro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Longatto-Filho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Scapulatempo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas</article-title>
<source/>Virchows Arch
          <year>2008</year>
<volume>452</volume>
<fpage>139</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1007/s00428-007-0558-5</pub-id>
<pub-id pub-id-type="pmid">18188595</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roche</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hiromasa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms</article-title>
<source/>Prog Nucleic Acid Res Mol Biol
          <year>2001</year>
<volume>70</volume>
<fpage>33</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1016/S0079-6603(01)70013-X</pub-id>
<pub-id pub-id-type="pmid">11642366</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koukourakis</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Giatromanolaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Sivridis</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma</article-title>
<source/>Cancer Res
          <year>2006</year>
<volume>66</volume>
<fpage>632</fpage>
<lpage>637</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3260</pub-id>
<pub-id pub-id-type="pmid">16423989</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wigfield</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Winter</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Giatromanolaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Koukourakis</surname>
<given-names>ML</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer</article-title>
<source/>Br J Cancer
          <year>2008</year>
<volume>98</volume>
<fpage>1975</fpage>
<lpage>1984</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6604356</pub-id>
<pub-id pub-id-type="pmid">18542064</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baumunk</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Reichelt</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hildebrandt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ebbing</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC)</article-title>
<source/>World J Urol
          <year>2013</year>
<volume>31</volume>
<fpage>1191</fpage>
<lpage>1196</lpage>
<pub-id pub-id-type="doi">10.1007/s00345-012-0874-5</pub-id>
<pub-id pub-id-type="pmid">22544372</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunt</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Aslam</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Beckert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ghani</surname>
<given-names>QP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms</article-title>
<source/>Antioxid Redox Signal
          <year>2007</year>
<volume>9</volume>
<fpage>1115</fpage>
<lpage>1124</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2007.1674</pub-id>
<pub-id pub-id-type="pmid">17567242</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeBerardinis</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lum</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Hatzivassiliou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>The biology of cancer: metabolic reprogramming fuels cell growth and proliferation</article-title>
<source/>Cell Metab
          <year>2008</year>
<volume>7</volume>
<fpage>11</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2007.10.002</pub-id>
<pub-id pub-id-type="pmid">18177721</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vander Heiden</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title>
<source/>Science
          <year>2009</year>
<volume>324</volume>
<fpage>1029</fpage>
<lpage>1033</lpage>
<pub-id pub-id-type="doi">10.1126/science.1160809</pub-id>
<pub-id pub-id-type="pmid">19460998</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McFate</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mohyeldin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Thakar</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Henriques</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells</article-title>
<source/>J Biol Chem
          <year>2008</year>
<volume>283</volume>
<fpage>22700</fpage>
<lpage>22708</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M801765200</pub-id>
<pub-id pub-id-type="pmid">18541534</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutendra</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dromparis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kinnaird</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stenson</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Haromy</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer</article-title>
<source/>Oncogene
          <year>2013</year>
<volume>32</volume>
<fpage>1638</fpage>
<lpage>1650</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2012.198</pub-id>
<pub-id pub-id-type="pmid">22614004</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbot</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>McCormack</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Reynet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hassall</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Buchan</surname>
<given-names>KW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells</article-title>
<source/>FEBS J
          <year>2005</year>
<volume>272</volume>
<fpage>3004</fpage>
<lpage>3014</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2005.04713.x</pub-id>
<pub-id pub-id-type="pmid">15955060</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hulver</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>McMillan</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Cline</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>ER</given-names>
</name>
</person-group>
<article-title>The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility</article-title>
<source/>Nutr Metab (Lond)
          <year>2014</year>
<volume>11</volume>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.1186/1743-7075-11-10</pub-id>
<pub-id pub-id-type="pmid">24520982</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>IK</given-names>
</name>
</person-group>
<article-title>The role of pyruvate dehydrogenase kinase in diabetes and obesity</article-title>
<source/>Diabetes Metab J
          <year>2014</year>
<volume>38</volume>
<fpage>181</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.4093/dmj.2014.38.3.181</pub-id>
<pub-id pub-id-type="pmid">25003070</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osthus</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc</article-title>
<source/>J Biol Chem
          <year>2000</year>
<volume>275</volume>
<fpage>21797</fpage>
<lpage>21800</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.C000023200</pub-id>
<pub-id pub-id-type="pmid">10823814</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van de Wetering</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sancho</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Verweij</surname>
<given-names>C</given-names>
</name>
<name>
<surname>de Lau</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Oving</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells</article-title>
<source/>Cell
          <year>2002</year>
<volume>111</volume>
<fpage>241</fpage>
<lpage>250</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(02)01014-0</pub-id>
<pub-id pub-id-type="pmid">12408868</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nusse</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Wnt signaling and stem cell control</article-title>
<source/>Cell Res
          <year>2008</year>
<volume>18</volume>
<fpage>523</fpage>
<lpage>527</lpage>
<pub-id pub-id-type="doi">10.1038/cr.2008.47</pub-id>
<pub-id pub-id-type="pmid">18392048</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niehrs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Acebron</surname>
<given-names>SP</given-names>
</name>
</person-group>
<article-title>Mitotic and mitogenic Wnt signalling</article-title>
<source/>EMBO J
          <year>2012</year>
<volume>31</volume>
<fpage>2705</fpage>
<lpage>2713</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2012.124</pub-id>
<pub-id pub-id-type="pmid">22617425</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wise</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>DeBerardinis</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Mancuso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sayed</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>XY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2008</year>
<volume>105</volume>
<fpage>18782</fpage>
<lpage>18787</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0810199105</pub-id>
<pub-id pub-id-type="pmid">19033189</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dang</surname>
<given-names>CV</given-names>
</name>
</person-group>
<article-title>Rethinking the Warburg effect with Myc micromanaging glutamine metabolism</article-title>
<source/>Cancer Res
          <year>2010</year>
<volume>70</volume>
<fpage>859</fpage>
<lpage>862</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3556</pub-id>
<pub-id pub-id-type="pmid">20086171</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Semenza</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>CV</given-names>
</name>
</person-group>
<article-title>Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1</article-title>
<source/>Mol Cell Biol
          <year>2007</year>
<volume>27</volume>
<fpage>7381</fpage>
<lpage>7393</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.00440-07</pub-id>
<pub-id pub-id-type="pmid">17785433</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldbeter</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Patterns of spatiotemporal organization in an allosteric enzyme model</article-title>
<source/>Proc Natl Acad Sci USA
          <year>1973</year>
<volume>70</volume>
<fpage>3255</fpage>
<lpage>3259</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.70.11.3255</pub-id>
<pub-id pub-id-type="pmid">4274133</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prigogine</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Nicolis</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Biological order, structure and instabilities</article-title>
<source/>Q Rev Biophys
          <year>1971</year>
<volume>4</volume>
<fpage>107</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1017/S0033583500000615</pub-id>
<pub-id pub-id-type="pmid">4257403</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mor</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Vousden</surname>
<given-names>KH</given-names>
</name>
</person-group>
<article-title>Control of glycolysis through regulation of PFK1: old friends and recent additions</article-title>
<source/>Cold Spring Harb Symp Quant Biol
          <year>2011</year>
<volume>76</volume>
<fpage>211</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="doi">10.1101/sqb.2011.76.010868</pub-id>
<pub-id pub-id-type="pmid">22096029</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chocarro-Calvo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Garcia-Martinez</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Ardila-Gonzalez</surname>
<given-names>S</given-names>
</name>
<name>
<surname>De la Vieja</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Garcia-Jimenez</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Glucose-induced beta-catenin acetylation enhances Wnt signaling in cancer</article-title>
<source/>Mol Cell
          <year>2013</year>
<volume>49</volume>
<fpage>474</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2012.11.022</pub-id>
<pub-id pub-id-type="pmid">23273980</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguilera</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Munoz-Sagastibelza</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Torrejon</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Borrero-Palacios</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Del Puerto-Nevado</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>47954</fpage>
<lpage>47965</lpage>
<pub-id pub-id-type="pmid">27323830</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khatami</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Is cancer a severe delayed hypersensitivity reaction and histamine a blueprint?</article-title>
<source/>Clin Transl Med
          <year>2016</year>
<volume>5</volume>
<fpage>35</fpage>
<pub-id pub-id-type="doi">10.1186/s40169-016-0108-3</pub-id>
<pub-id pub-id-type="pmid">27558401</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bax</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Bloxam</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>Energy metabolism and glycolysis in human placental trophoblast cells during differentiation</article-title>
<source/>Biochim Biophys Acta
          <year>1997</year>
<volume>1319</volume>
<fpage>283</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="doi">10.1016/S0005-2728(96)00169-7</pub-id>
<pub-id pub-id-type="pmid">9131049</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feller</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Parwaresch</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Myofibroblast as a major cellular constituent of villous stroma in human placenta</article-title>
<source/>Placenta
          <year>1985</year>
<volume>6</volume>
<fpage>405</fpage>
<lpage>415</lpage>
<pub-id pub-id-type="doi">10.1016/S0143-4004(85)80017-5</pub-id>
<pub-id pub-id-type="pmid">2866507</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiavegato</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bochaton-Piallat</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>D’Amore</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sartore</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gabbiani</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Expression of myosin heavy chain isoforms in mammary epithelial cells and in myofibroblasts from different fibrotic settings during neoplasia</article-title>
<source/>Virchows Arch
          <year>1995</year>
<volume>426</volume>
<fpage>77</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1007/BF00194701</pub-id>
<pub-id pub-id-type="pmid">7535633</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shinomiya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fujitani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Key</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biochemical and immunohistochemical characterization of the isoforms of myosin and actin in human placenta</article-title>
<source/>Placenta
          <year>2011</year>
<volume>32</volume>
<fpage>347</fpage>
<lpage>355</lpage>
<pub-id pub-id-type="doi">10.1016/j.placenta.2011.02.008</pub-id>
<pub-id pub-id-type="pmid">21420731</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lecarpentier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Guerin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hebert</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ultraslow myosin molecular motors of placental contractile stem villi in humans</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<fpage>e108814</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0108814</pub-id>
<pub-id pub-id-type="pmid">25268142</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecarpentier</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Claes</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Hebert</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Krokidis</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Blanc</surname>
<given-names>FX</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Statistical mechanics of the human placenta: a stationary state of a near-equilibrium system in a linear regime</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<fpage>e0142471</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0142471</pub-id>
<pub-id pub-id-type="pmid">26569482</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carthy</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Garmaroudi</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>McManus</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>Wnt3a induces myofibroblast differentiation by upregulating TGF-beta signaling through SMAD2 in a beta-catenin-dependent manner</article-title>
<source/>PLoS ONE
          <year>2011</year>
<volume>6</volume>
<fpage>e19809</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0019809</pub-id>
<pub-id pub-id-type="pmid">21611174</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernard</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Logsdon</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Ravi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Persons</surname>
<given-names>BP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metabolic reprogramming is required for myofibroblast contractility and differentiation</article-title>
<source/>J Biol Chem
          <year>2015</year>
<volume>290</volume>
<fpage>25427</fpage>
<lpage>25438</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M115.646984</pub-id>
<pub-id pub-id-type="pmid">26318453</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polakis</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Drugging Wnt signalling in cancer</article-title>
<source/>EMBO J
          <year>2012</year>
<volume>31</volume>
<fpage>2737</fpage>
<lpage>2746</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2012.126</pub-id>
<pub-id pub-id-type="pmid">22617421</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polakis</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Wnt signaling in cancer</article-title>
<source/>Cold Spring Harb Perspect Biol
          <year>2012</year>
<pub-id pub-id-type="pmid">22438566</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuchs</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The tortoise and the hair: slow-cycling cells in the stem cell race</article-title>
<source/>Cell
          <year>2009</year>
<volume>137</volume>
<fpage>811</fpage>
<lpage>819</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2009.05.002</pub-id>
<pub-id pub-id-type="pmid">19490891</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morin</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Sparks</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Korinek</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Clevers</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC</article-title>
<source/>Science
          <year>1997</year>
<volume>275</volume>
<fpage>1787</fpage>
<lpage>1790</lpage>
<pub-id pub-id-type="doi">10.1126/science.275.5307.1787</pub-id>
<pub-id pub-id-type="pmid">9065402</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Najdi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Holcombe</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Waterman</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Wnt signaling and colon carcinogenesis: beyond APC</article-title>
<source/>J Carcinog
          <year>2011</year>
<volume>10</volume>
<fpage>5</fpage>
<pub-id pub-id-type="doi">10.4103/1477-3163.78111</pub-id>
<pub-id pub-id-type="pmid">21483657</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarraf</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Kum</surname>
<given-names>JB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss-of-function mutations in PPAR gamma associated with human colon cancer</article-title>
<source/>Mol Cell
          <year>1999</year>
<volume>3</volume>
<fpage>799</fpage>
<lpage>804</lpage>
<pub-id pub-id-type="doi">10.1016/S1097-2765(01)80012-5</pub-id>
<pub-id pub-id-type="pmid">10394368</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girnun</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Drori</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sarraf</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>APC-dependent suppression of colon carcinogenesis by PPAR gamma</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2002</year>
<volume>99</volume>
<fpage>13771</fpage>
<lpage>13776</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.162480299</pub-id>
<pub-id pub-id-type="pmid">12370429</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brockman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>RN</given-names>
</name>
</person-group>
<article-title>Activation of PPAR gamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells</article-title>
<source/>Gastroenterology
          <year>1998</year>
<volume>115</volume>
<fpage>1049</fpage>
<lpage>1055</lpage>
<pub-id pub-id-type="doi">10.1016/S0016-5085(98)70072-1</pub-id>
<pub-id pub-id-type="pmid">9797355</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kojima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yoshiura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hiraishi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Terano</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells</article-title>
<source/>Gut
          <year>2002</year>
<volume>50</volume>
<fpage>658</fpage>
<lpage>664</lpage>
<pub-id pub-id-type="doi">10.1136/gut.50.5.658</pub-id>
<pub-id pub-id-type="pmid">11950812</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osawa</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ishimine</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fujisawa</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice</article-title>
<source/>Gastroenterology
          <year>2003</year>
<volume>124</volume>
<fpage>361</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="doi">10.1053/gast.2003.50067</pub-id>
<pub-id pub-id-type="pmid">12557142</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cesario</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Bissonnette</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Lamph</surname>
<given-names>WW</given-names>
</name>
</person-group>
<article-title>Differentiation and growth inhibition mediated via the RXR: PPAR gamma heterodimer in colon cancer</article-title>
<source/>Cancer Lett
          <year>2006</year>
<volume>240</volume>
<fpage>225</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2005.09.010</pub-id>
<pub-id pub-id-type="pmid">16271436</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarraf</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>D</given-names>
</name>
<name>
<surname>King</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>DeAngelo</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differentiation and reversal of malignant changes in colon cancer through PPARgamma</article-title>
<source/>Nat Med
          <year>1998</year>
<volume>4</volume>
<fpage>1046</fpage>
<lpage>1052</lpage>
<pub-id pub-id-type="doi">10.1038/2030</pub-id>
<pub-id pub-id-type="pmid">9734398</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grommes</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Landreth</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Heneka</surname>
<given-names>MT</given-names>
</name>
</person-group>
<article-title>Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists</article-title>
<source/>Lancet Oncol
          <year>2004</year>
<volume>5</volume>
<fpage>419</fpage>
<lpage>429</lpage>
<pub-id pub-id-type="doi">10.1016/S1470-2045(04)01509-8</pub-id>
<pub-id pub-id-type="pmid">15231248</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McAlpine</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Barak</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Matise</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cormier</surname>
<given-names>RT</given-names>
</name>
</person-group>
<article-title>Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice</article-title>
<source/>Int J Cancer
          <year>2006</year>
<volume>119</volume>
<fpage>2339</fpage>
<lpage>2346</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.22115</pub-id>
<pub-id pub-id-type="pmid">16858678</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sarraf</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tontonoz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>KJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Terminal differentiation of human breast cancer through PPAR gamma</article-title>
<source/>Mol Cell
          <year>1998</year>
<volume>1</volume>
<fpage>465</fpage>
<lpage>470</lpage>
<pub-id pub-id-type="doi">10.1016/S1097-2765(00)80047-7</pub-id>
<pub-id pub-id-type="pmid">9660931</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clay</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Namen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Atsumi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Willingham</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>High</surname>
<given-names>KP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells</article-title>
<source/>Carcinogenesis
          <year>1999</year>
<volume>20</volume>
<fpage>1905</fpage>
<lpage>1911</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/20.10.1905</pub-id>
<pub-id pub-id-type="pmid">10506103</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pignatelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cocca</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Perez-Castillo</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line</article-title>
<source/>Oncogene
          <year>2003</year>
<volume>22</volume>
<fpage>5446</fpage>
<lpage>5450</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1206824</pub-id>
<pub-id pub-id-type="pmid">12934104</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elstner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Koshizuka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice</article-title>
<source/>Proc Natl Acad Sci USA
          <year>1998</year>
<volume>95</volume>
<fpage>8806</fpage>
<lpage>8811</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.95.15.8806</pub-id>
<pub-id pub-id-type="pmid">9671760</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inoue</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kawahito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tsubouchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kohno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists</article-title>
<source/>Biochem Biophys Res Commun
          <year>2001</year>
<volume>287</volume>
<fpage>727</fpage>
<lpage>732</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.2001.5640</pub-id>
<pub-id pub-id-type="pmid">11563856</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>YF</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Breyer</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Breyer</surname>
<given-names>MD</given-names>
</name>
</person-group>
<article-title>Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death</article-title>
<source/>Neoplasia
          <year>1999</year>
<volume>1</volume>
<fpage>330</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="doi">10.1038/sj.neo.7900050</pub-id>
<pub-id pub-id-type="pmid">10935488</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lodillinsky</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Umerez</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Jasnis</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Casabe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sandes</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bacillus Calmette-Guerin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells</article-title>
<source/>Int J Mol Med
          <year>2006</year>
<volume>17</volume>
<fpage>269</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="pmid">16391825</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radhakrishnan</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Gartel</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines</article-title>
<source/>Cell Cycle
          <year>2005</year>
<volume>4</volume>
<fpage>582</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="doi">10.4161/cc.4.4.1583</pub-id>
<pub-id pub-id-type="pmid">15738655</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sarraf</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kroll</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Aiyer</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2000</year>
<volume>97</volume>
<fpage>10990</fpage>
<lpage>10995</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.180329197</pub-id>
<pub-id pub-id-type="pmid">10984506</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>ZW</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>DQ</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>JP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines</article-title>
<source/>Acta Pharmacol Sin
          <year>2005</year>
<volume>26</volume>
<fpage>753</fpage>
<lpage>761</lpage>
<pub-id pub-id-type="doi">10.1111/j.1745-7254.2005.00753.x</pub-id>
<pub-id pub-id-type="pmid">15916743</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsubouchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kawahito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mukai</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis</article-title>
<source/>Biochem Biophys Res Commun
          <year>2000</year>
<volume>270</volume>
<fpage>400</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.2000.2436</pub-id>
<pub-id pub-id-type="pmid">10753637</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Hur</surname>
<given-names>GY</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PPAR-gamma agonist increase gefitinib’s antitumor activity through PTEN expression</article-title>
<source/>Lung Cancer
          <year>2006</year>
<volume>51</volume>
<fpage>297</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="doi">10.1016/j.lungcan.2005.10.010</pub-id>
<pub-id pub-id-type="pmid">16386327</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>YY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone</article-title>
<source/>Int J Cancer
          <year>2006</year>
<volume>118</volume>
<fpage>773</fpage>
<lpage>779</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.21361</pub-id>
<pub-id pub-id-type="pmid">16094629</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sato</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ishihara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kawashima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Moriyama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Suetsugu</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists</article-title>
<source/>Br J Cancer
          <year>2000</year>
<volume>83</volume>
<fpage>1394</fpage>
<lpage>1400</lpage>
<pub-id pub-id-type="doi">10.1054/bjoc.2000.1457</pub-id>
<pub-id pub-id-type="pmid">11044367</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Okumura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Motomura</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Fujimoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kawabata</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells</article-title>
<source/>FEBS Lett
          <year>1999</year>
<volume>455</volume>
<fpage>135</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(99)00871-6</pub-id>
<pub-id pub-id-type="pmid">10428487</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mafune</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice</article-title>
<source/>Cancer Res
          <year>2005</year>
<volume>65</volume>
<fpage>4769</fpage>
<lpage>4774</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2293</pub-id>
<pub-id pub-id-type="pmid">15930296</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>ZR</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>SZ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese</article-title>
<source/>Aliment Pharmacol Ther
          <year>2006</year>
<volume>23</volume>
<fpage>289</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02739.x</pub-id>
<pub-id pub-id-type="pmid">16393309</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tontonoz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Ming</surname>
<given-names>UT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activators of the nuclear receptor PPARgamma enhance colon polyp formation</article-title>
<source/>Nat Med
          <year>1998</year>
<volume>4</volume>
<fpage>1058</fpage>
<lpage>1061</lpage>
<pub-id pub-id-type="doi">10.1038/2042</pub-id>
<pub-id pub-id-type="pmid">9734400</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lefebvre</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Desreumaux</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Najib</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fruchart</surname>
<given-names>JC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6 J-APCMin/+ mice</article-title>
<source/>Nat Med
          <year>1998</year>
<volume>4</volume>
<fpage>1053</fpage>
<lpage>1057</lpage>
<pub-id pub-id-type="doi">10.1038/2036</pub-id>
<pub-id pub-id-type="pmid">9734399</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Lamprecht</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Edelmann</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kopelovich</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6 J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1 ± double mutant mice</article-title>
<source/>Int J Cancer
          <year>2005</year>
<volume>116</volume>
<fpage>495</fpage>
<lpage>499</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.21018</pub-id>
<pub-id pub-id-type="pmid">15818612</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulke</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Demetri</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Sharpless</surname>
<given-names>NE</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Shivdasani</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer</article-title>
<source/>Cancer J
          <year>2002</year>
<volume>8</volume>
<fpage>395</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1097/00130404-200209000-00010</pub-id>
<pub-id pub-id-type="pmid">12416897</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venkata</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cabot</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Monteith</surname>
<given-names>GR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast</article-title>
<source/>Toxicol Lett
          <year>2006</year>
<volume>163</volume>
<fpage>224</fpage>
<lpage>234</lpage>
<pub-id pub-id-type="doi">10.1016/j.toxlet.2005.11.001</pub-id>
<pub-id pub-id-type="pmid">16326050</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Livolsi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PPAR gamma signaling exacerbates mammary gland tumor development</article-title>
<source/>Genes Dev
          <year>2004</year>
<volume>18</volume>
<fpage>528</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="doi">10.1101/gad.1167804</pub-id>
<pub-id pub-id-type="pmid">15037548</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Miyoshi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Claudio</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Siebenlist</surname>
<given-names>UK</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>FJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<fpage>17830</fpage>
<lpage>17835</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M200186200</pub-id>
<pub-id pub-id-type="pmid">11884400</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papadaki</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mylona</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Giannopoulou</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Markaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Keramopoulos</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PPARgamma expression in breast cancer: clinical value and correlation with ERbeta</article-title>
<source/>Histopathology
          <year>2005</year>
<volume>46</volume>
<fpage>37</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2559.2005.02056.x</pub-id>
<pub-id pub-id-type="pmid">15656884</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burstein</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Demetri</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sarraf</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Spiegelman</surname>
<given-names>BM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study</article-title>
<source/>Breast Cancer Res Treat
          <year>2003</year>
<volume>79</volume>
<fpage>391</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="doi">10.1023/A:1024038127156</pub-id>
<pub-id pub-id-type="pmid">12846423</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seargent</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Gill</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation</article-title>
<source/>Br J Pharmacol
          <year>2004</year>
<volume>143</volume>
<fpage>933</fpage>
<lpage>937</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjp.0705973</pub-id>
<pub-id pub-id-type="pmid">15533890</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Egerod</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Iversen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Thorup</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Storgaard</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo</article-title>
<source/>Biomarkers
          <year>2005</year>
<volume>10</volume>
<fpage>295</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="doi">10.1080/13547500500218682</pub-id>
<pub-id pub-id-type="pmid">16240504</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshimura</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Matsuyama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Segawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hase</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mitsuhashi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists</article-title>
<source/>Int J Cancer
          <year>2003</year>
<volume>104</volume>
<fpage>597</fpage>
<lpage>602</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.10980</pub-id>
<pub-id pub-id-type="pmid">12594814</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lea</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Sura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Desbordes</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists</article-title>
<source/>Anticancer Res
          <year>2004</year>
<volume>24</volume>
<fpage>2765</fpage>
<lpage>2771</lpage>
<pub-id pub-id-type="pmid">15517883</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<mixed-citation publication-type="other">Simons AL, Orcutt KP, Madsen JM, Scarbrough PM, Spitz DR (2012) Oxidative stress in cancer biology and therapy. In: Spitz DR, Dornfeld KJ, Krishnan J, Gius D (eds) Oxidative Stress in Applied Research and Clinical Practice. Humana Press, New York. doi:10.1007/978-1-61779-397-4</mixed-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alao</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention</article-title>
<source/>Mol Cancer
          <year>2007</year>
<volume>6</volume>
<fpage>24</fpage>
<pub-id pub-id-type="doi">10.1186/1476-4598-6-24</pub-id>
<pub-id pub-id-type="pmid">17407548</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicholson</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>NG</given-names>
</name>
</person-group>
<article-title>The protein kinase B/Akt signalling pathway in human malignancy</article-title>
<source/>Cell Signal
          <year>2002</year>
<volume>14</volume>
<fpage>381</fpage>
<lpage>395</lpage>
<pub-id pub-id-type="doi">10.1016/S0898-6568(01)00271-6</pub-id>
<pub-id pub-id-type="pmid">11882383</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manning</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>LC</given-names>
</name>
</person-group>
<article-title>AKT/PKB signaling: navigating downstream</article-title>
<source/>Cell
          <year>2007</year>
<volume>129</volume>
<fpage>1261</fpage>
<lpage>1274</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.06.009</pub-id>
<pub-id pub-id-type="pmid">17604717</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karar</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Maity</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>PI3 K/AKT/mTOR pathway in angiogenesis</article-title>
<source/>Front Mol Neurosci
          <year>2011</year>
<volume>4</volume>
<fpage>51</fpage>
<pub-id pub-id-type="doi">10.3389/fnmol.2011.00051</pub-id>
<pub-id pub-id-type="pmid">22144946</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Georgescu</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>PTEN tumor suppressor network in PI3 K-Akt pathway control</article-title>
<source/>Genes Cancer
          <year>2010</year>
<volume>1</volume>
<fpage>1170</fpage>
<lpage>1177</lpage>
<pub-id pub-id-type="doi">10.1177/1947601911407325</pub-id>
<pub-id pub-id-type="pmid">21779440</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castellone</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Teramoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Druey</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Gutkind</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis</article-title>
<source/>Science
          <year>2005</year>
<volume>310</volume>
<fpage>1504</fpage>
<lpage>1510</lpage>
<pub-id pub-id-type="doi">10.1126/science.1116221</pub-id>
<pub-id pub-id-type="pmid">16293724</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer</article-title>
<source/>J Biol Chem
          <year>2005</year>
<volume>280</volume>
<fpage>26565</fpage>
<lpage>26572</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M413056200</pub-id>
<pub-id pub-id-type="pmid">15899904</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ricchi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zarrilli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Di Palma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Acquaviva</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy</article-title>
<source/>Br J Cancer
          <year>2003</year>
<volume>88</volume>
<fpage>803</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6600829</pub-id>
<pub-id pub-id-type="pmid">12644813</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goessling</surname>
<given-names>W</given-names>
</name>
<name>
<surname>North</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Loewer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration</article-title>
<source/>Cell
          <year>2009</year>
<volume>136</volume>
<fpage>1136</fpage>
<lpage>1147</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2009.01.015</pub-id>
<pub-id pub-id-type="pmid">19303855</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Nellore</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Patsoukis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Petkova</surname>
<given-names>V</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/beta-catenin pathway and alters immune reconstitution after UCBT</article-title>
<source/>Blood Cancer J
          <year>2014</year>
<volume>4</volume>
<fpage>e178</fpage>
<pub-id pub-id-type="doi">10.1038/bcj.2013.75</pub-id>
<pub-id pub-id-type="pmid">24442207</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Prostaglandin E2 alters Wnt-dependent migration and proliferation in neuroectodermal stem cells: implications for autism spectrum disorders</article-title>
<source/>Cell Commun Signal
          <year>2014</year>
<volume>12</volume>
<fpage>19</fpage>
<pub-id pub-id-type="doi">10.1186/1478-811X-12-19</pub-id>
<pub-id pub-id-type="pmid">24656144</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hazra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Peebles</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Dubinett</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>The role of PPARgamma in the cyclooxygenase pathway in lung cancer</article-title>
<source/>PPAR Res
          <year>2008</year>
<volume>2008</volume>
<fpage>790568</fpage>
<pub-id pub-id-type="doi">10.1155/2008/790568</pub-id>
<pub-id pub-id-type="pmid">18769553</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>LaPointe</surname>
<given-names>MC</given-names>
</name>
</person-group>
<article-title>PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes</article-title>
<source/>Hypertension
          <year>2003</year>
<volume>42</volume>
<fpage>844</fpage>
<lpage>850</lpage>
<pub-id pub-id-type="doi">10.1161/01.HYP.0000085332.69777.D1</pub-id>
<pub-id pub-id-type="pmid">12885795</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savvidis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Koutsilieris</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Circadian rhythm disruption in cancer biology</article-title>
<source/>Mol Med
          <year>2012</year>
<volume>18</volume>
<fpage>1249</fpage>
<lpage>1260</lpage>
<pub-id pub-id-type="doi">10.2119/molmed.2012.00077</pub-id>
<pub-id pub-id-type="pmid">22811066</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodwin</surname>
<given-names>BC</given-names>
</name>
</person-group>
<article-title>Oscillatory behavior in enzymatic control processes</article-title>
<source/>Adv Enzyme Regul
          <year>1965</year>
<volume>3</volume>
<fpage>425</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1016/0065-2571(65)90067-1</pub-id>
<pub-id pub-id-type="pmid">5861813</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardin</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Rosbash</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Feedback of the drosophila period gene product on circadian cycling of its messenger RNA levels</article-title>
<source/>Nature
          <year>1990</year>
<volume>343</volume>
<fpage>536</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="doi">10.1038/343536a0</pub-id>
<pub-id pub-id-type="pmid">2105471</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldbeter</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Computational approaches to cellular rhythms</article-title>
<source/>Nature
          <year>2002</year>
<volume>420</volume>
<fpage>238</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1038/nature01259</pub-id>
<pub-id pub-id-type="pmid">12432409</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gekakis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Staknis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Wilsbacher</surname>
<given-names>LD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of the CLOCK protein in the mammalian circadian mechanism</article-title>
<source/>Science
          <year>1998</year>
<volume>280</volume>
<fpage>1564</fpage>
<lpage>1569</lpage>
<pub-id pub-id-type="doi">10.1126/science.280.5369.1564</pub-id>
<pub-id pub-id-type="pmid">9616112</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hogenesch</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>YZ</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bradfield</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors</article-title>
<source/>Proc Natl Acad Sci USA
          <year>1998</year>
<volume>95</volume>
<fpage>5474</fpage>
<lpage>5479</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.95.10.5474</pub-id>
<pub-id pub-id-type="pmid">9576906</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schibler</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Sassone-Corsi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>A web of circadian pacemakers</article-title>
<source/>Cell
          <year>2002</year>
<volume>111</volume>
<fpage>919</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(02)01225-4</pub-id>
<pub-id pub-id-type="pmid">12507418</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reppert</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>Coordination of circadian timing in mammals</article-title>
<source/>Nature
          <year>2002</year>
<volume>418</volume>
<fpage>935</fpage>
<lpage>941</lpage>
<pub-id pub-id-type="doi">10.1038/nature00965</pub-id>
<pub-id pub-id-type="pmid">12198538</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sassone-Corsi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Metabolism and cancer: the circadian clock connection</article-title>
<source/>Nat Rev Cancer
          <year>2009</year>
<volume>9</volume>
<fpage>886</fpage>
<lpage>896</lpage>
<pub-id pub-id-type="doi">10.1038/nrc2747</pub-id>
<pub-id pub-id-type="pmid">19935677</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wood</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Hrushesky</surname>
<given-names>WJ</given-names>
</name>
</person-group>
<article-title>Clock genes and cancer</article-title>
<source/>Integr Cancer Ther
          <year>2009</year>
<volume>8</volume>
<fpage>303</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="doi">10.1177/1534735409355292</pub-id>
<pub-id pub-id-type="pmid">20042409</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>The free energy cost of accurate biochemical oscillations</article-title>
<source/>Nat Phys
          <year>2015</year>
<volume>11</volume>
<fpage>772</fpage>
<lpage>778</lpage>
<pub-id pub-id-type="doi">10.1038/nphys3412</pub-id>
<pub-id pub-id-type="pmid">26566392</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paschos</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Kunieda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Obesity in mice with adipocyte-specific deletion of clock component Arntl</article-title>
<source/>Nat Med
          <year>2012</year>
<volume>18</volume>
<fpage>1768</fpage>
<lpage>1777</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2979</pub-id>
<pub-id pub-id-type="pmid">23142819</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Ansell</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Ohmori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>EY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice</article-title>
<source/>J Biochem
          <year>2009</year>
<volume>145</volume>
<fpage>289</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1093/jb/mvn167</pub-id>
<pub-id pub-id-type="pmid">19106159</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winter</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Bosnoyan-Collins</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pinnaduwage</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Andrulis</surname>
<given-names>IL</given-names>
</name>
</person-group>
<article-title>Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors</article-title>
<source/>Neoplasia
          <year>2007</year>
<volume>9</volume>
<fpage>797</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="doi">10.1593/neo.07595</pub-id>
<pub-id pub-id-type="pmid">17971899</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Gery</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dashti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A role for the clock gene per1 in prostate cancer</article-title>
<source/>Cancer Res
          <year>2009</year>
<volume>69</volume>
<fpage>7619</fpage>
<lpage>7625</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4199</pub-id>
<pub-id pub-id-type="pmid">19752089</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kusumi</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Period is involved in the proliferation of human pancreatic MIA-PaCa2 cancer cells by TNF-alpha</article-title>
<source/>Biomed Res
          <year>2008</year>
<volume>29</volume>
<fpage>99</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.2220/biomedres.29.99</pub-id>
<pub-id pub-id-type="pmid">18480551</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafaie</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kallay</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sauerzapf</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bonner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kriwanek</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer</article-title>
<source/>Mol Carcinog
          <year>2009</year>
<volume>48</volume>
<fpage>642</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="doi">10.1002/mc.20510</pub-id>
<pub-id pub-id-type="pmid">19148895</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>HH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered expression of circadian clock genes in human chronic myeloid leukemia</article-title>
<source/>J Biol Rhythms
          <year>2011</year>
<volume>26</volume>
<fpage>136</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1177/0748730410395527</pub-id>
<pub-id pub-id-type="pmid">21454294</pub-id>
</element-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujioka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Takashima</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shigeyoshi</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Circadian rhythm generation in a glioma cell line</article-title>
<source/>Biochem Biophys Res Commun
          <year>2006</year>
<volume>346</volume>
<fpage>169</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2006.05.094</pub-id>
<pub-id pub-id-type="pmid">16750513</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>ZF</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>SZ</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>SC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deregulated expression of the Per1 and Per2 in human gliomas</article-title>
<source/>Can J Neurol Sci
          <year>2010</year>
<volume>37</volume>
<fpage>365</fpage>
<lpage>370</lpage>
<pub-id pub-id-type="doi">10.1017/S031716710001026X</pub-id>
<pub-id pub-id-type="pmid">20481271</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>PPARs integrate the mammalian clock and energy metabolism</article-title>
<source/>PPAR Res
          <year>2014</year>
<volume>2014</volume>
<fpage>653017</fpage>
<pub-id pub-id-type="pmid">24693278</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Downes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Bookout</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nuclear receptor expression links the circadian clock to metabolism</article-title>
<source/>Cell
          <year>2006</year>
<volume>126</volume>
<fpage>801</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.06.050</pub-id>
<pub-id pub-id-type="pmid">16923398</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Aoyagi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>McClain</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>RM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Systemic PPARgamma deletion impairs circadian rhythms of behavior and metabolism</article-title>
<source/>PLoS ONE
          <year>2012</year>
<volume>7</volume>
<fpage>e38117</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0038117</pub-id>
<pub-id pub-id-type="pmid">22899986</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Borjigin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Transcriptional coactivator PGC-1alpha integrates the mammalian clock and energy metabolism</article-title>
<source/>Nature
          <year>2007</year>
<volume>447</volume>
<fpage>477</fpage>
<lpage>481</lpage>
<pub-id pub-id-type="doi">10.1038/nature05767</pub-id>
<pub-id pub-id-type="pmid">17476214</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bode</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of PGC1alpha in cancer metabolism and its therapeutic implications</article-title>
<source/>Mol Cancer Ther
          <year>2016</year>
<volume>15</volume>
<fpage>774</fpage>
<lpage>782</lpage>
<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0621</pub-id>
<pub-id pub-id-type="pmid">27197257</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duez</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Staels</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Nuclear receptors linking circadian rhythms and cardiometabolic control</article-title>
<source/>Arterioscler Thromb Vasc Biol
          <year>2010</year>
<volume>30</volume>
<fpage>1529</fpage>
<lpage>1534</lpage>
<pub-id pub-id-type="doi">10.1161/ATVBAHA.110.209098</pub-id>
<pub-id pub-id-type="pmid">20631353</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>